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ABSTRACT 
Purpose: The purpose of the current study was to explore if the laryngeal dose can be reduced 
by using two Intensity-Modulated Radiation Therapy (IMRT) techniques: whole neck field IMRT 
technique (WF-IMRT) vs. junctioned IMRT (J-IMRT). The effect on planning target volumes 
(PTVs) coverage and laryngeal sparing was evaluated. 
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Method: WF-IMRT technique consisted of a single IMRT plan including the primary tumor, the 
superior and inferior neck to the level of the clavicular heads. The larynx was defined as an 
organ at risk extending superiorly to cover the arythenoid cartilages and inferiorly to include the 
crycoid cartilage. The J-IMRT technique consisted of an IMRT plan for the primary tumor and 
the superior neck, matched to a conventional antero-posterior opposing lower neck fields at the 
level of the thyroid notch. A central block was used for the anterior lower neck field at the level 
of the larynx in order to restrict the dose to the larynx. Ten oropharyngeal cancer cases were 
analyzed. Both the primary site and bilateral regional lymphatics were included in the 
radiotherapy targets. 
Results: The averaged V95 for the PTV57.6 was 99.2% for WF-IMRT technique when 
compared with 97.4% (p=0.02) for J-IMRT. The averaged V95 for the PTV64 was 99.9% for 
WF-IMRT technique when compared with 98.9% (p=0.02) for J-IMRT and the averaged V95 for 
the PT70 was 100.0% for WF-IMRT technique when compared with 99.5% (p=0.04) for J-IMRT. 
The averaged mean laryngeal dose was 18 Gy with both techniques. The averaged mean dose 
within the matchline volumes were 69.3Gy for WF-MRT vs 66.2 Gy  for J-IMRT (p=0.03). 
Conclusion: WF-IMRT technique appears to offer an optimal coverage of the target volumes and a 
mean dose to the larynx similar with J-IMRT and should be further evaluated in clinical trials. 
 
INTRODUCTION 
The optimal management of oropharyngeal cancer is multidisciplinary and radiotherapy is a part 
of treatment approach for most of these patients. The greatest challenge with radiotherapy for 
oropharyngeal cancer is to maximize loco-regional disease control, while minimizing the 
morbidity and treatment-related toxicity to surrounding normal tissues, including the larynx [1]. 
With the development of the Intensity-Modulated Radiation Therapy (IMRT) technique, head 
and neck cancers have been treated with good results as reported by various investigators [2,3]. 
4 
 
IMRT has been shown to offer better target homogeneity and tumor coverage and normal organ 
sparing [3,4]. However, the use of IMRT tends to unnecessarily deliver higher dose to the larynx 
[5]. More than one decade ago, Mendenhall et al. discouraged the practice of including the 
uninvolved larynx in the radiation fields when the non-laryngeal primary tumor site could be 
adequately covered by placing the inferior border of the opposed lateral fields at the level of the 
thyroid notch. The superior section of the plan was matched to a conventional anterior neck field 
resulting in very low doses to the larynx, which was typically blocked on the anterior field [1]. 
Emerging data from patients with long term follow up have showed that irradiation of the normal 
larynx is associated with laryngeal dysfunction affecting patients’ quality of life in head and neck 
cancer survivors, treated with radiation therapy [6,7]. Furthermore, recent studies by Eisburch et 
al. have shown that sparing larynx improves dysphagia and aspiration [8].  
 
The current study was undertaken to determine if the laryngeal dose can be reduced when 
using IMRT techniques including the attempt to spare the larynx based on given dose 
constraints for this organ at risk when a whole-neck field IMRT (WF-IMRT) is chosen or the use 
of a junctioned IMRT (J-IMRT) consisting of an IMRT plan for the primary non-laryngeal tumor 
and the superior neck, matched with a conventional opposed antero-posterior lower neck fields 
at the level of the thyroid notch. 
 
MATERIALS & METHODS 
Patient Selection 
Ten consecutive patients diagnosed with stage IV oropharyngeal squamous cell carcinoma and 
treated between September 2006 and January 2007, at the University of Pennsylvania, 
Department of Radiation Oncology were included in the current study. Approval was granted by 
the Institutional Review Board for conducting this study. Nine patients were diagnosed with 
stage IV A disease (T1-3N2bM0) and one patient with stage IV B disease (T2N3M0). The nodal 
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disease at the neck in four cases extended inferiorly to the level of the glottic larynx. All patients 
were treated with IMRT to the primary site and the bilateral cervical lymph nodes. Two treatment 
plans were generated for each patient using WF-IMRT and J-IMRT techniques and the 
dosimetric data was compared between the two treatment plans. The coverage of the target 
volumes and the dose to the larynx were compared using the resulting dose volume histograms 
and the following dose parameters: V100 and V95 for the targets, and mean laryngeal dose. 
V100 was defined as the percent of the target volume covered by 100% of the prescribed dose 
and V95 was defined as the percent of the target volume covered by 95% of the prescribed 
dose.  
 
Radiotherapy treatment planning  
All patients underwent a CT-based planning for IMRT using a 3 mm CT slice thickness to cover 
the oropharyngeal tumors and bilateral cervical lymph nodes.  Gross tumor volume (GTV) was 
defined as the grossly visible tumor and metastatic lymphadenopathy on physical examination 
and imaging studies (contrast CT and/or MRI). Clinical target volume (CTV1) encompassed the 
GTV and the adjacent tissue supposed to contain microscopic, subclinical tumor extension and 
first echelon nodes. The uninvolved nodal areas that were at lower risk of subclinical disease, 
treated prophylactically were included in the CTV2 volume. Planning target volume (PTV) was 
obtained by expansion of the CTVs to compensate for setup uncertainty, typically by 3-5 mm. 
The PTV was adjusted appropriately, to respect the 
anatomical bounders located in close proximity to the target volumes. Briefly, 70.4 Gy in 32 
fractions were prescribed to the PTVs of the gross disease (PTV70.4), 64 Gy in 32 fractions to 
the PTVs of high risk subclinical disease (subclinical disease at the surrounding area of the 
primary tumor and first echelon lymph nodes) (PTV64), and 57.6 in 32 fractions to the PTVs 
of the lesser risk sublicnical disease (the rest of the neck nodal targets) (PTV57.6), 
respectively. All patients in this group were treated with a simultaneous in-field boost IMRT 
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technique. Inverse treatment planning was performed using the treatment planning system 
Eclipse v.8.10, anisotropic analytical algorithm (AAA). For each patient, a plan with 7-9 coplanar 
sliding-window IMRT beams of 6MV was generated. The J-IMRT technique consisted of an 
IMRT plan for the primary tumor and the superior neck above the level of the arythenoids. The 
lower neck and the supraclavicular fossae were treated using a conventional half-beam blocked 
antero-posterior opposing neck fields matched with the upper neck IMRT plan at the level of the 
thyroid notch. A central block was used for the anterior lower neck field at the level of the larynx 
in order to restrict the dose to this organ at risk, and a full central cord block was used for the 
posterior field to protect the spinal cord. The upper neck IMRT was matched with the lower neck 
field using a split-beam technique and there was no gap between the superior 
IMRT fields and the inferior neck fields. Matchline volumes have been defined to include 3 mm 
bellow and above the actual matchline for the PTVs and dose distribution has been evaluated in 
this region. WF-IMRT technique consisted of a single IMRT 
plan including the primary tumor, the superior and inferior neck to the level of the clavicular 
heads, avoiding the matchline level present with J-IMRT technique. The larynx was 
considered an organ of risk and was defined as superiorly covering the arythenoid cartilages 
and inferiorly including the cricoid cartilage. The lateral borders of the planning organ at risk 
volume (PRV) of the larynx were contoured 3-5 mm away from the medial borders of the neck 
PTVs in order to avoid underdosage in these areas of the target volumes. Other organs at risk 
included spinal cord (from the top of C1 vertebral body to approximately T3, just below the 
lowest slice level that has PTV in it), brainstem, middle ears, bilateral parotid glands, mandible, 
and the esophagus (from the bottom of cricoid cartilage to the thoracic inlet). The treatment 
planning addressed the targets coverage objectives as the highest priority, whereas the organs 
at risk dosimetric goals were secondary, with the exception of maximal spinal cord and braistem 
dose. The dose constraints for the organs at risk are summarized in Table 1.  Several iterations 
were performed for optimization, aiming to reduce the mean dose to the larynx to the lowest 
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possible, while maintaining the target coverage and the constraints to the other organs at risk 
according to the dose constraints and priority levels of the target volumes and organs at risk.  
 
Dose-volume histograms 
The dose-volume histograms (DVHs) of the target volumes and of the organs at risk were 
analyzed with the emphasis on the target volumes coverage and the laryngeal dose. 
 
Statistical methods 
A Wilcoxon sign rank test was employed to determine if there was a statistically significant 
difference between target coverage and laryngeal dose levels achieved for WF-IMRT versus    
J-IMRT technique. In this study p-values less than 0.05 were considered significant.  
RESULTS 
The averaged V100 for the PTV57.6 was 97.7% for WF-IMRT technique when compared with 
88.0% (p= 0.005) for J-IMRT, suggesting a better coverage of PTV57.6 by 100% isodose line 
with WF-IMRT. The averaged V95 for the PTV57.6 was 99.2% for WF-IMRT technique when 
compared with 97.4% (p=0.02) for J-IMRT. The averaged V100 for the PTV64 was 98.5% for 
WF-IMRT technique when compared with 94.4% (p= 0.24) for J-IMRT. The averaged V95 for 
the PTV64 was 99.9% for WF-IMRT technique when compared with 98.9% (p=0.02) for J-IMRT. 
The averaged V100 for the PTV70 was 97.4% for WF-IMRT technique when compared with 
94.1% (p= 0.12) for J-IMRT. The averaged V95 for the PT70 was 100.0% for WF-IMRT 
technique when compared with 99.5% (p=0.04) for J-IMRT.  Averaged dosimetrical parameters 
to the target volumes and the organs at risk are represented in Table 2. The dose volume 
histograms for the target volumes (PTV57.6) are represented in Figure 1a. 
 
8 
 
The averaged mean laryngeal dose was 17.6 Gy for WF-IMRT technique when compared with 
18.2 Gy (p= 0.44) for J-IMRT. See Table 2. The dose volume histograms for the larynx are 
represented in Figure 1b.  
 
Moreover, only 40 % of the laryngeal volume received approximately 18 Gy with both IMRT 
techniques.  Only 10% of the laryngeal volume receives > 20 Gy with WF-IMRT. See Figure 1b. 
 
The averaged mean dose within the matchline volumes were 69.3Gy (SD +1.9) for WF-MRT vs 
66.2 Gy (SD + 5.13) for J-IMRT (p=0.03). 
 
DISCUSSION 
The use of IMRT has been shown to unnecessarily distribute higher dose of radiation to the 
larynx when the larynx sparing is not attempted as part of the IMRT treatment planning [5,9,10]. 
To avoid this situation, Amdur et al. used a J-IMRT technique with a superior-neck IMRT 
matched with a conventional anterior lower neck field at the level of the thyroid notch, for 
patients with non-laryngeal head and neck cancer. Amdur et al. demonstrated that the dose to 
the normal larynx can be substantially reduced by shielding this organ on an anterior lower 
neck field [5]. For the WF-IMRT that included both the primary site and the upper and lower 
cervical lymph nodes, the mean laryngeal dose was 35 Gy in this study. This dose was much 
higher than the mean laryngeal dose of 17 Gy obtained when the normal larynx was shielded 
in the conventional anterior lower neck field by using a J-IMRT technique [5]. However, our 
study revealed that the mean laryngeal dose may be significantly reduced using 
WF-IMRT, when the larynx is defined as an organ at risk and is incorporated into the IMRT 
optimization process, without compromising the target volumes coverage or the 
accomplishment of dosimetric goals elsewhere in the treatment plan. The averaged mean 
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laryngeal dose was 18 Gy using WF-IMRT, identical with the averaged mean laryngeal dose 
achieved with J-IMRT. Furthermore, the current study results suggest that laryngeal doses 
obtained by using WF-IMRT may be further reduced to values below 25 Gy previously reported 
in the literature [11]. Webster et al. demonstrated that the dose to the larynx was decreased 
significantly from a reported mean dose of approximately 45-50 Gy, usually described when 
larynx sparing is not attempted with WF-IMRT, to a mean dose of 25-40 Gy if the larynx is 
considered an organ at risk and is incorporated into the WF-IMRT optimization process [9-11].  
 
Studies evaluating the dose distribution close to the matchline between the opposed lateral 
fields and the anterior lower neck field as used by conventional radiotherapy for the treatment of 
non-laryngeal head and neck cancers showed that there may be a few millimeters of increased 
or decreased dose at or near field junction in the neck [12]. The clinical significance of these 
dosimetric findings remains unclear. Bubenzer et al.  showed, using thermolaminescent 
dosimetry  measurements on a Rando phantom, that the dose homogeneity along the matchline 
and critical structures are of concern if the upper head and neck fields were treated with IMRT 
and the lower neck with conventional (supraclavicular) fixed beam using a J-IMRT 
monoisocentric technique similar to the one employed in our study [13]. The averaged mean 
dose within the matchline volume were 69.3Gy for WF-MRT vs 66.2 Gy for J-IMRT (p=0.03) in 
the present study.  
 
Dose inhomogeneity across the matchline has been further investigated and new techniques to 
mitigate the matchline dosimetrical uncertainties have been explored and reported in the 
literature [14-16]. Amdur et al. reportedly move the upper border of the anterior lower neck field 
few millimeters superiorly at least once during the radiotherapy treatment, in order to reduce the 
dose inhomogeneity at the matchline between upper neck IMRT and conventional anterior lower 
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neck field [14,15]. Furthermore, a dynamic supraclavicular field-matching technique for head 
and neck cancer patients treated with IMRT has been developed by the same group [16]. 
 
Conclusions 
Taking in consideration the limitation of the present study including a small number of patients, 
our results suggest that the WF-IMRT technique may achieve an optimal coverage of the target 
volumes and mean dose to the larynx similar with J-IMRT, while avoiding the dosimetric 
uncertainty at the matchline present with J-IMRT. Clinical validation is required to determine 
whether this dosimetric benefit can be translated into meaningful clinical gains for 
oropharyngeal cancer patients. 
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Table 1. Dose constraints for planning organ at risk volumes  
 
PRV Mean dose to the 
PRV (Gy) 
Maximum dose to the 
PRV (Gy) 
Spinal cord PRV  50 
Brain Stem PRV  52 
Parotid glands PRVs 26  
Mandible PRV   70 
Esophagus PRV < 45  
Larynx PRV Reduce the dose as much as possible.  
PRV, planning organ at risk volume 
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Table 2. Averaged dosimetrical parameters to the target volumes and the organs at risk 
 
Variable WF-IMRT J-IMRT SD p value 
V100 for PTV70 97.4% 94.1% 1.69 0.12 
V95 for PTV70 100% 99.5% 0.26 0.04 
V100 for PTV64 98.45 94.4% 2.17 0.24 
V95 for PTV64 99.9% 98.9% 0.43 0.02 
V100 for 
PTV57.6 
97.7% 88.0% 2.21 0.005 
V95 for PTV57.6 99.2% 97.4% 0.59 0.02 
Spinal cord 
maximum dose 
43.7 Gy 46.8 Gy 1.07   0.01 
Esophageal 
maximum dose 
37.7 Gy 59.5 Gy 1.73 0.005 
14 
 
Lungs maximum 
dose 
42.2 Gy 57.1 Gy 2.53 0.01 
Laryngeal 
maximum dose 
30.4 Gy 49.2 Gy 3.59 0.006 
Laryngeal 
minimum dose  
14.9 Gy 10.3 Gy 0.45 0.005 
Laryngeal mean 
dose 
17.6 Gy 18.2 Gy 0.84 0.44 
 
 
 
Figure 1a. Dose-volume histogram for the target volumes (PTV57.6) using whole-neck field 
IMRT (WF-IMRT) and junctioned IMRT (J-IMRT) 
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Figure 1b. Dose-volume histogram for the larynx using whole-neck field IMRT (WF-IMRT) and 
junctioned IMRT (J-IMRT) 
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